ALPHAMAB ONCOLO.DL-000002 (3NK) — Capital Reinvestment Ratio
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Capital Reinvestment Ratio of 0.10x as of December 2024, meaning it reinvests 0% of its operating cash flow (€212.34 Million) in capital expenditures (€21.77 Million). See ALPHAMAB ONCOLO.DL-000002 balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
ALPHAMAB ONCOLO.DL-000002 Capital Reinvestment Ratio (2024–2024)
This chart tracks ALPHAMAB ONCOLO.DL-000002's Capital Reinvestment Ratio across 1 annual periods. Check ALPHAMAB ONCOLO.DL-000002 (3NK) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for ALPHAMAB ONCOLO.DL-000002 (2024–2024)
Year-by-year Capital Reinvestment Ratio for ALPHAMAB ONCOLO.DL-000002 from 2024 to 2024. For live market cap and broader valuation context, see 3NK company net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.10x | €212.34 Million | €21.77 Million | — |